Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells

Pierre F, Regan CF, Chevrel MC, Siddiqui-Jain A, Macalino D, Streiner N, Drygin D, Haddach M, O'Brien SE, Rice WG, Ryckman DM
Bioorg Med Chem Lett (2012), Vol. 22 pages 3327-31

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells

Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, Ruzzene M.
PLoS One (2012), Vol. 7 page 49193

Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond

Kim J, Kim SH.
Arch Pharm Res. (2012), Vol. 35, pages 1293-6

CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy

Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.
Mol Cancer Ther (2012), Vol. 11, pages 994-1005

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.
Mol Cell Biochem (2011), Vol. 356, pages 37-43

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer

Drygin D, Ho CB, Omori M, Bliesath J, Proffitt C, Rice R, Siddiqui-Jain A, O'Brien S, Padgett C, Lim JK, Anderes K, Rice WG, Ryckman D.
Biochem Biophys Res Commun (2011), Vol. 415, pages 163-7

ATP site-directed inhibitors of protein kinase CK2: an update

Sarno S, Papinutto E, Franchin C, Bain J, Elliott M, Meggio F, Kazimierczuk Z, Orzeszko A, Zanotti G, Battistutta R, Pinna LA.
Curr Top Med Chem (2011), Vol. 11, pages 1340-51

Casein Kinase II: an attractive target for anti-cancer drug design

Hanif IM, Hanif IM, Shazib MA, Ahmad KA, Pervaiz S.
Int J Biochem Cell Biol (2010), Vol. 42, pages 1602-5

Protein kinase CK2 in health and disease: CK2: a key player in cancer biology

Trembley JH, Wang G, Unger G, Slaton J, Ahmed K.
Cell Mol Life Sci (2009) Vol. 66, pages 1858-67

Comparative analysis of CK2 expression and function in tumor cell lines displaying sensitivity vs. resistance to chemical induced apoptosis

G. Di Maira, F. Brustolon, K. Tosoni, S. Belli, S.D. Krämer, L.A. Pinna and M. Ruzzene
Molecular and Cellular Biochemistry (2008), Vol. 316 pages 155-61

Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2

J.S. Duncan and D.W. Litchfield
Biochimica et Biophysica Acta (2008), Vol. 1784 pages 33-47

Protein Kinase CK2 in Human Diseases

B. Guerra and O.G. Issinger
Current Medicinal Chemistry (2008), Vol. 15 pages 1870-1886

Inhibition of casein kinase 2 enhances the death ligand- and natural killer cell-induced hepatocellular carcinoma cell death

H.R. Kim, K. Kim, K.H. Lee, S.J. Kim and J. Kim
Clinical and Experimental Immunology (2008), Vol. 152 pages 336-344

CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells

D. Llobet, N. Eritja, M. Encinas, N. Llecha, A. Yeramian, J. Pallares, A. Sorolla, F.J. Gonzalez-Tallada, X. Matias-Guiu and X. Dolcet
Oncogene (2008), Vol. 27 pages 2513-2524

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

S.E. Perea, O. Reyes, I. Baladron, Y. Perera, H. Farina, J. Gil, A. Rodriguez, D. Bacardi, J.L. Marcelo, K. Cosme, M. Cruz, C. Valenzuela, P.A. López-Saura, Y. Puchades, J.M. Serrano, O. Mendoza, L. Castellanos, A. Sanchez, L. Betancourt, V. Besada, R. Silva, E. López, V. Falcón, I. Hernández, M. Solares, A. Santana, A. Díz, T. Ramos, C. López, J. Ariosa, L.J. González, H. Garay, D. Gómez, R. Gómez, D.F. Alonso, H. Sigman, L. Herrera and B. Acevedo
Molecular and Cellular Biochemistry (2008), Vol. 316 pages 163-167

Systemic administration of a peptide that impairs the Protein Kinase (CK2) phosphorylation reduces solid tumor growth in mice

Y. Perera, H.G. Farina, I. Hernádez, O. Mendoza, J.M. Serrano, O. Reyes, D.E. Gómez, R.E. Gómez, B.E. Acevedo, D.F. Alonso and S.E. Perea
International Journal of Cancer (2008), Vol. 122 pages 57-62

Protein kinase CK2 as a druggable target

S. Sarno and L.A. Pinna
Molecular BioSystems (2008), Vol. 4 pages 889-894

Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells

G. Wang, K.A. Ahmad, N.H. Harris and K. Ahmed
Molecular and Cellular Biochemistry (2008), Vol. 316 pages 91-97

Casein kinase II inhibition induces apoptosis in pancreatic cancer cells

R. Hamacher, D. Saur, R. Fritsch, M. Reichert, R.M. Schmid and G. Schneider
Oncology Reports (2007), Vol. 18 pages 695-701

Protein Kinase CK2α as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia

J.S. Kim, J.I. Eom, J-W Cheong, A.J. Choi, J.K. Lee, W.I. Yang and Y.H. Min
Clinical Cancer Research (2007), Vol. 13 pages 1019-1028

Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells

Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K.
Mol Cancer Ther (2007), Vol. 6, pages 1006-12

Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia

Kim JS, Eom JI, Cheong JW, Choi AJ, Lee JK, Yang WI, Min YH.
Clin Cancer Res (2007), Vol. 13, pages 1019-28

Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer

Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, Cochet C.
Eur J Cancer (2007), Vol. 43, pages 928-34

Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT

Yde CW, Frogne T, Lykkesfeldt AE, Fichtner I, Issinger OG, Stenvang J.
Cancer Lett. (2007), Vol. 256, pages 229-37